|A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer.|
|PMID: 16061869 Owner: NLM Status: MEDLINE|
|PURPOSE: To evaluate the effects of the proteasome inhibitor bortezomib on tumor growth in patients with advanced colorectal cancer, and to explore the relationship between correlative studies and clinical outcome. DESIGN: Bortezomib (1.3 mg/m(2)) was administered i.v. on days 1, 4, 8, and 11 of a 21-day cycle. Tumor response was assessed after every two cycles. Tumor biopsies were done prior to treatment and on day 9 of the first treatment cycle. Biopsies were examined for Ser(32/36)-IkappaB, Ser(276)-nuclear factor kappaB (NFkappaB), hypoxia-inducible factor-1alpha (HIF-1alpha), carbonic anhydrase IX (CAIX), p53, and microvessel density using immunohistochemistry. RESULTS: Nineteen patients received 42 cycles (range 1-4) of bortezomib. No objective response was seen; three patients had stable disease at cycle 2, two patients had progressive disease after cycle 1, and 11 patients had progressive disease at cycle 2. Of the three patients with stable disease, one had progressive disease after cycle 4, and two were withdrawn due to toxicity. The median time to progression was 5.1 weeks (95% confidence interval, 5.1-11.1 weeks). There was a significant increase in the expression of HIF-1alpha relative to its transcriptional target CAIX following bortezomib, and a similar effect was also observed in a companion study using a human tumor xenograft model. Expression of p53, Ser(276)-NFkappaB, and Ser(32/36)-IkappaB was unchanged. CONCLUSION: Single agent bortezomib is inactive in metastatic colorectal cancer. Using this regimen, there was no detectable effect on NFkappaB, but a significant accumulation of HIF-1alpha was seen relative to CAIX. This suggests that proteasome inhibition alters the response to tumor hypoxia, and further investigation of this effect is indicated.|
|Helen Mackay; David Hedley; Pierre Major; Carol Townsley; Mary Mackenzie; Mark Vincent; Pam Degendorfer; Ming-Sound Tsao; Trudey Nicklee; Diana Birle; John Wright; Lillian Siu; Malcolm Moore; Amit Oza|
Related Documents :
|9806649 - Expression of p53 protein and resistance to preoperative chemotherapy in locally advanc...
20576719 - Bcirg 001 molecular analysis: prognostic factors in node-positive breast cancer patient...
10974929 - Immunohistochemical study of p53 in non-small cell lung cancer before and after preoper...
9816029 - Localized adenocarcinoma of the lung: oncogene expression of erbb-2 and p53 in 150 pati...
10682269 - Immunohistochemical detection of mutant p53 protein in regional lymph nodes is associat...
22956069 - When is a lymph node dissection a lymph node dissection? the number of lymph nodes rese...
6992979 - Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma. a comparative...
23137549 - Clinical impact of ki-67 labeling index in non-small cell lung cancer.
22949139 - Post-transplant consolidation therapy using thalidomide alone for the patients with mul...
|Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't|
|Title: Clinical cancer research : an official journal of the American Association for Cancer Research Volume: 11 ISSN: 1078-0432 ISO Abbreviation: Clin. Cancer Res. Publication Date: 2005 Aug|
|Created Date: 2005-08-02 Completed Date: 2006-01-05 Revised Date: 2006-11-15|
Medline Journal Info:
|Nlm Unique ID: 9502500 Medline TA: Clin Cancer Res Country: United States|
|Languages: eng Pagination: 5526-33 Citation Subset: IM|
|Princess Margaret Phase II Consortium, Toronto, Canada.|
|APA/MLA Format Download EndNote Download BibTex|
Aged, 80 and over
Antigens, Neoplasm / metabolism
Antineoplastic Agents / pharmacology*
Boronic Acids / pharmacology*
Carbonic Anhydrases / metabolism
Colorectal Neoplasms / drug therapy*, pathology*
Enzyme Inhibitors / pharmacology
Liver / pathology
NF-kappa B / metabolism
Proteasome Endopeptidase Complex / antagonists & inhibitors
Pyrazines / pharmacology*
Serine / chemistry
Tumor Suppressor Protein p53 / metabolism
|0/Antigens, Neoplasm; 0/Antineoplastic Agents; 0/Boronic Acids; 0/Enzyme Inhibitors; 0/NF-kappa B; 0/Pyrazines; 0/Tumor Suppressor Protein p53; 0/bortezomib; 56-45-1/Serine; EC 188.8.131.52/Proteasome Endopeptidase Complex; EC 184.108.40.206/CA9 protein, human; EC 220.127.116.11/Carbonic Anhydrases|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell respons...
Next Document: Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiot...